The v-fms oncogene product of the McDonough strain of feline sarcoma virus is a member of the receptor tyrosine kinase family. Its cellular counterpart, the c-fms product, is the receptor for colony-stimulating factor 1 (CSF-1) of macrophages. We have reanalyzed the v-fms gene by direct sequencing of a biologically active clone. An additional A nucleotide was detected in position 2810 of the published v-fms sequence. The frameshift changed the COOH-terminal sequence of the v-fms protein from -R-937-G-P-P-L-COOH to -Q-937-R-T-P-P-V-A-R-COOH. Antibodies against a synthetic peptide representing this new sequence precipitated the v-fms proteins from transformed NRK cells as well as from feline sarcoma virus (McDonough)-infected feline fibroblasts. We show by tryptic peptide mapping that threonine 939 present in the new sequence is phosphorylated by a yet unknown serine/threonine kinase in vivo. In chicken fibroblasts expressing the v-fms gene, this phosphorylation clearly depended on the addition of exogenous CSF-1. Furthermore, addition of CSF-1 appeared to activate the serine/threonine kinase, as judged by phosphorylation of the synthetic peptide QRTPPVAR.
The v-fms gene was determined to be the transforming oncogene of the McDonough strain of feline sarcoma virus (SM-FeSV). The gene product belongs to the family of receptor tyrosine kinases (9) . It is translated as a gag-fms fusion protein which is cotranslationally N glycosylated and processed by proteolytic cleavage to generate p55gag and gp120v-fs. The latter remains associated with membranes of the endoplasmic reticulum. About 10 to 15% of the gpl2Ov-fms molecules are transported via the Golgi apparatus to the plasma membrane and are concomitantly processed by additional glycosylation of the amino-terminal domain to yield gpl4Ov-fms (2, 14, 18) . Cell surface expression of the glycoprotein is a prerequisite for cell transformation (22) .
The cytoplasmic domain of gpl4Ov-fms exhibits tyrosine kinase activity, and although it is four-to fivefold weaker than that of other viral tyrosine kinases, this activity is clearly required for cell transformation (30, 32) .
The cellular counterpart of v-fms, c-fms, was identified as the receptor for macrophage colony-stimulating factor 1 (CSF-1) (26). At the amino acid level, the feline c-fms product (34) and the v-fms product (9) revealed only six point mutations within the extracellular domain and three amino acid exchanges within the 445 amino acids of the cytoplasmic domain. In addition, the 11 carboxyl-terminal amino acids of the v-fms product were replaced by 50 unrelated amino acids present in the c-fms product. Roussel et al. (19) reported that a single point mutation in the extracellular domain of the human c-fms product activated its transforming potential. However, Woolford et al. (34) demonstrated that two point mutations within the extracellular domain in addition to a C-terminal modification were * Corresponding author. t Present address: European Molecular Biology Laboratory, Heidelberg, Germany. required for fully establishing the transforming potency of the feline c-fms protein. Furthermore, a replacement of the v-fms tail sequence by that derived from the c-fms sequence markedly reduced the transformation potential (34) .
To determine the role of the C-terminal domain, we prepared peptide-specific antibodies against the published C-terminal sequence of the v-fms product (9) . This antibody, however, failed to recognize the v-fms proteins in immune precipitations or on Western immunoblots (27a). We therefore concluded that the previously published v-fms sequence might be wrong and set out to correct it by direct sequencing of a biologically active clone. We show that the new C terminus contains a consensus sequence for a variety of serine/threonine-specific protein kinases. We demonstrate that this site can be phosphorylated by cdc2 kinase in vitro and becomes phosphorylated in vivo by a yet undefined protein kinase. In v-fms-expressing chicken cells, this phosphorylation was enhanced by exogenous CSF-1, which simultaneously activated the fms-specific tyrosine kinase and the serine/threonine kinase, as judged by phosphoryla- (29) , were grown in scribed previously (32) . Antisera against synthetic peptides were prepared in rabbits as described previously (28) . Peptides were synthesized on a Milligen model 9050 automated peptide synthesizer using Fmoc chemistry. The anti-cdc2 serum (8) was kindly provided by G. Draetta (European Molecular Biology Laboratory, Heidelberg, Germany).
DNA sequencing. DNA sequences were determined by direct sequencing of pSM-FeSV on both strands, using a set of synthetic oligonucleotides in the chain termination method of Sanger et al. (24) . In comparison with the previously published sequence (9) , six nucleotide changes were detected. All of these alterations (Table 1) , four of them being located in wobble positions, one causing an amino acid exchange in position 680, and one leading to a frameshift in codon position 937, correspond to the sequence reported for the feline c-fms gene (34) .
Radiolabeling. Subconfluent v-fms-transformed NRK cells in 5-or 10-cm petri dishes were labeled for 6 h with 32p; (1 mCi/ml; 1,850 MBq; carrier free; Amersham Buchler.)
Immunoprecipitation, kinase assay, phosphoamino acid analysis, and tryptic peptide mapping. Tyrosine-specific protein kinase assays were performed exactly as described previously (31, 32) . In vitro phosphorylation reactions of synthetic peptides were performed according to a protocol published by Countaway et al. (6) . A total of 106 CEC infected with NB4 or DS3 virus (29) were grown on 50-mm petri dishes. Cells were incubated for 2 days in the absence of fetal calf serum and then treated for 30 min at 37°C with 1 ml of 120 mM NaCl-6 mM KCl-1.2 mM CaCI2-1 mM MgCl2-25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.4)-30 ,uM bovine serum albumin. The cells were then incubated for 10 min on ice with medium without or with CSF-1 (1,000 U/ml) before the temperature was raised to 37°C for 5 min. The medium was aspirated, and the cells were harvested on ice by scraping into 0.5 ml of 25 mM HEPES (pH 7.4)-S5 mM EGTA-50 mM NaF-10 ,ug of leupeptin per ml. After homogenization (20 passages through a 26-gauge needle), phosphorylation reactions were performed at 22°C, using 5 ,u1 of the cell extract, 12.5 p.l of 50 mM HEPES (pH 7.4)-20 mM MgCl2, and 2 p.1 of synthetic peptide (10 mg/ml). The phosphorylation reaction was initiated by the addition of 10 p.1 of 50 ,uM [_y-32PIATP (100 Ci/nmol) and was terminated by the addition of 10 pI of 90% formic acid. The phosphorylated synthetic peptide was separated from the reaction mixture by thinlayer electrophoresis at 1 kV for 40 min at pH 3.5, using glacial acetic acid-pyridine-water (100:10:1,890) as a solvent. The phosphopeptide was extracted from the plate, and radioactivity was measured by liquid scintillation counting. 
RESULTS
Correction of the v-fms sequence. To distinguish between the cellular and the viral gene products, we raised peptidespecific antibodies against the different C-terminal tail structures as published previously (9, 34) . The antibodies directed against the v-fms sequence, however, failed to recognize any polypeptide from SM-FeSV-transformed NRK cells on Western blots or in immunoprecipitation reactions. We therefore reanalyzed first the 3' coding region and subsequently the entire v-fms gene. For this purpose, we used the biologically active clone, pSM-FeSV, originally applied by Hampe et al. (9) (kindly provided by C. J. Sherr). Six nucleotide divergences were detected in comparison with the previously published v-fms sequence ( Table 1) . Each of these alterations matched the sequence of the feline c-fms sequence (34) , indicating that the nucleotide changes were not simply mutations that had occurred during replication of the plasmid. As shown in Fig. 1 , an additional A or T nucleotide was detected in position 2810. This insertion caused a frameshift that affected the five C-terminal amino acid residues of the published sequence, -R-937-G-P-P-L-
COOH.
A peptide antibody against the newly found C-terminal sequence reacts with the v-fms products. As shown in Fig. 2 , antibodies raised against the newly determined C-terminal sequence, NH2-(Tyr)-Gln-Arg-Thr-Pro-Pro-Val-Ala-Arg-COOH, precipitated each of the v-fms-specific polypeptides derived from v-fms-transformed NRK cells (Fig. 2A, lane 3) as well as from SM-FeSV-infected cat fibroblasts (Fig. 2B,  lane 3) . The immune reactions with the peptide-specific antibody were specifically inhibited by the addition of the synthetic peptide (Fig. 2, lanes 4) . In contrast, formation of immune complexes was not inhibited by the peptide when the polyclonal antibody was used (compare lanes 1 and 2). Similar data were obtained with Rat-2 cells which had been transfected with the v-fms oncogene (data not shown).
The correct sequence contains a consensus sequence for proline-directed protein kinases. The newly found sequence, Arg-Thr-939-Pro-Pro-Val-Ala-Arg, is closely related to the substrate consensus sequence of cdc2 kinase, basic-Thr/SerPro-X-basic (13, 25) . However, as shown in Table 2 , this sequence could also serve as a substrate for other kinases such as the proline-directed kinase (33) or the growth factorregulated protein kinase (6), both of which were recently characterized as microtubule-associated protein (MAP) kinase (27) Fig. 3A , lane 2, the synthetic peptide QRTPPVAR was phosphorylated by cdc2 kinase at the threonine residue (Fig. 3B) . Furthermore, this phosphorylated species was not obtained when either cdc2 kinase (Fig. 3A, lane 1) or the peptide (Fig. 3A, lane 3) had been omitted from the incubation mixture.
Threonine 939 of gpl4Q-fms is phosphorylated in vivo. To gain further knowledge about the phosphorylation pattern of v-fms molecules, we first compared the in vivo phosphorylation of feline c-fms and v-fms polypeptides. Rat-2 cells expressing either the feline c-fms or the v-fms gene (34) were labeled with 32p; for 6 h and then lysed for immunoprecipitation with a v-fms-specific antibody. In accordance with previous observations (32) and as shown in Fig. 4A , only gpl4Ov-fms and gpl5Oc-f?s (molecular species that are both present at the plasma membrane) were phosphorylated in vivo. Material underlying these bands was further analyzed for its phosphoamino acid content. As shown in Fig. 4B , gpl5O-fms contained phosphoserine only (panel 2). In con- Proline-directed protein kinase -X-Ser/Thr-Pro-X- 33 (ERK/MAP kinase) 3 Growth factor-regulated kinase -Pro-Leu-Thr-Pro-Ser-Gly-Glu-Ala- trast, gp140v--fms contained phosphoserine, phosphotyrosine, and phosphothreonine (panel 1). Tryptic peptide mapping of gpl4Ov-fms (Fig. 5A ) yielded several spots, one of which, designated spot A, clearly comigrated with the synthetic peptide that had been phosphorylated in vitro and had subsequently been treated with trypsin ( Fig. SB and C) . Spot A was not present in the tryptic peptide mapping of gp150'cfns (data not shown). These data suggest that threonine 939 of the gpl4OvJrns molecules is indeed phosphorylated in vivo. However, at present we cannot exclude the possibility that threonine sites other than threonine 939 are also phosphorylated.
Threonine 939 phosphorylation becomes enhanced by stimulation of cells with CSF-1. We have recently established a v-fms-expressing chicken cell system that is especially advantageous for studying the initial steps of the CSF-1- h, and then incubated for 5 min in medium with or without 1,000 U of CSF-1 per ml. Cell lysates were then subjected to fms-specific immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The gp140v-fns bands from untreated (A) and CSF-1-treated (B) cells were excised from the gels, and phosphoamino acid analyses were performed. p-S, phosphoserine; p-T, phosphothreonine; p-Y, phosphotyrosine.
induced mitogenic cascade (29) . Chicken cells infected with a recombinant NB4-virus expressed high levels of gp140v-^fs but displayed an otherwise normal phenotype as long as CSF-1 was omitted from the growth medium. We used this system to study whether the addition of CSF-1 to the culture medium had an effect on threonine 939 phosphorylation. Sister cultures of NB4-infected CEC were kept for 2 days in medium containing 0.5% fetal calf serum and then metabolically labeled with 32p; for 6 h prior to stimulation with or without CSF-1. Figure 6 demonstrates that 5 min after stimulation with CSF-1, the content of both phosphotyrosine and phosphothreonine in gpl4Ov-fms molecules was significantly increased. These data suggest that CSF-1 not only stimulates the fms-specific tyrosine kinase but has an additional activating effect on an as yet unknown serine/threonine kinase.
Threonine 939 kinase is activated by the addition of CSF-1. The increased phosphorylation state of the v-fms polypeptide at threonine could be caused by an allosteric conformational change of the v-fms molecules, thus exposing the carboxy-terminal tail to a constitutively activated serine/ threonine kinase. Alternatively, this kinase by itself could (Fig. 4A, lane 2) and the in vitro-phosphorylated synthetic peptide (Fig. 3A, lane 2) were isolated and incubated with trypsin (300 ,ug/ml) for 20 h. The products were analyzed by two-dimensional electrophoresis and chromatography as described previously (31) . (A) Peptides obtained from gpl4Ov-fms; (B) product derived from the synthetic peptide; (C) coelectrophoresis and chromatography of material from panels A and B. Spot A, phosphopeptide derived from gpl4Ov-fns; spot a, synthetic phosphopeptide. Each value represents the mean of four independent experiments. become stimulated through the CSF-1-induced mitogenic cascade. To distinguish between these possibilities, we assayed the activity of the putative protein kinase in cell homogenates from CSF-1-stimulated and nonstimulated NB4-infected cells. For this purpose, the synthetic peptide QRTPPVAR was used as a substrate as described by Countaway et al. (6) . These authors observed a 3.5-fold activation of a serine/threonine kinase in cells treated with epidermal growth factor (EGF).
In our experiments, CSF-1 treatment of NB4-infected CEC for 5 min caused a rapid 3.7-fold increase in protein kinase activity, as judged by phosphorylation of the synthetic peptide substrate (Fig. 7) . (1, 15) kinase contain tyrosine phosphorylation sites at their C-terminal ends. By phosphorylation of these tyrosine residues, the tyrosine kinase activity is somewhat suppressed (11) . The feline c-fms protein also contains a tyrosine residue at position 977 within the C-terminal region. Furthermore, the six carboxy-terminal residues, Asn-AsnTyr-Gln-Phe-Cys-COOH, are conserved in c-fms polypeptides from human, mouse, cat, and chicken cells (2a, 7, 23, 33) . We have been unable to demonstrate any phosphorylation of this site under a variety of conditions (27a); a mutation of this residue into phenylalanine, however, enhanced the transforming potency of the activated human c-fms protein (20, 21) . In addition, Woolford et al. (34) reported that a replacement of C-terminal sequences of v-fms by those of c-fms reduced the transforming potency of the v-fms protein. Taken together, these observations suggest that the C-terminal domain of the c-fis protein could indeed contribute to the regulation of its tyrosine kinase activity.
It is not clear whether phosphorylation of threonine 939 induces a conformational change in the v-fms molecules and whether this modification alters their tyrosine kinase activity, as reported for the c-src and c-Ick proteins. We performed some preliminary in vitro experiments to address this question. In these assays, threonine 939 phosphorylation was first established by incubation with cdc-2 kinase as reported previously (31) , before the tyrosine kinase activity toward the substrate poly(Glu-Tyr) was determined. Under these experimental conditions, we repeatedly observed an approximately twofold increase of the v-fms-specific tyrosine kinase activity, suggesting that threonine 939 phosphorylation upregulates the tyrosine kinase. It remains to be shown, however, whether phosphorylation at threonine 939 in vivo indeed provides a means to fine-tune the oncogenic potential of gp140v f's molecules. Clearly, a threonine 939 mutant will be a valuable tool for use in addressing this question.
We have reported previously that v-fms-expressing chicken fibroblasts differ from mammalian cells in that they retain a normal phenotype despite the expression of high levels of gp14Ov-fPs molecules at their cell surface (29) . In this system, exogenous CSF-1 exerts two major effects, detectable within minutes after the addition of the growth factor. First, as expected, the v-fms-specific tyrosine becomes activated, resulting in a rapid autophosphorylation of the gpl4Ov-fms molecules at several tyrosine residues. Second, as demonstrated in this study, threonine 939 of the gpl4Ov-fms molecules becomes phosphorylated at the same rate, and so far we have been unable to uncouple the tyrosine and threonine phosphorylation reactions. We show here that CSF-1 indeed activates within 5 min one or more serine/threonine kinases which are capable of phosphorylating the synthetic peptide QRTPPVAR, representing the C-terminal end of the v-fms molecule.
Unfortunately, we can only speculate about the nature of this unknown kinase. Since antibodies were available to enrich cdc2 kinase, we used this kinase for our in vitro experiments. However, cdc2 kinase is inactive in Go or early G1 (8) . Therefore, it seems highly unlikely that it should play a role in the phosphorylation of v-fms proteins. A prolinedirected kinase with a molecular mass of 45 kD has been described to be active even in Go (33) . This kinase activity VOL. 65, 1991 on January 27, 2018 by guest http://jvi.asm.org/ Downloaded from was reported to transiently increase in PC12 pheochromocytoma cells following treatment with nerve growth factor. Another candidate kinase could be a growth factor-regulated kinase belonging to the MAP kinase family (6, 27) (3) . Phosphorylation of the EGF receptor involves threonine 669, a major phosphorylation site (6) . A mutation of this site was reported to alter both the substrate specificity and the ligand-induced internalization of the EGF receptor (10) . It is tempting to speculate that the unknown kinase itself is a substrate of the fms-specific tyrosine kinase. Furthermore, this kinase could be involved in transmitting the mitogenic signal by phosphorylating other substrates. Attempts to identify and characterize this kinase are under way in our laboratory.
